目的 研究针对慢性盆腔炎应用散结镇痛胶囊和头孢地尼联合治疗的临床效果。方法 纳入新疆医科大学第一附属医院2022年1月—2024年11月收治的88例慢性盆腔炎患者，进行分组（随机数字表法）研究，每组各44例。对照组口服头孢地尼胶囊，0.1 g/次，3次/d。以此为基础，治疗组加用散结镇痛胶囊治疗，餐后30 min口服，4粒/次，3次/d。两组疗程14 d。评估两组临床疗效，比较治疗前后两组相关评分[简式抑郁–焦虑–压力量表（DASS-21）、慢性盆腔炎功能量表（FS-CPID）评分]，盆腔包块最大径，血液流变学指标血浆黏度（PV）、红细胞聚集指数（EAI）及血清白细胞介素-1β（IL-1β）、IL-6水平。结果 治疗组总有效率是95.45%，较对照组的81.82%更高（P＜0.05）。同治疗前相比，两组病情各项评分（主症、次症、盆腔局部体征等）和总分在治疗后都降低（P＜0.05），DASS-21评分、盆腔包块最大径亦降低（P＜0.05）；治疗组较对照组更低（P＜0.05）。同治疗前相比，两组患者FS-CPID评分在治疗后都增加（P＜0.05），治疗组较对照组更高（P＜0.05）。治疗后，两组PV、EAI和血清IL-1β、IL-6水平都低于组内治疗前（P＜0.05），且治疗后治疗组血液流变学指标和血清因子水平明显低于对照组（P＜0.05）。结论 散结镇痛胶囊联合头孢地尼治疗慢性盆腔炎能有效促进患者症状、体征减轻及盆腔包块消除，抑制盆腔血液循环障碍和炎症反应，利于整体改善患者病情和生活质量，缓解不良情绪。

Objective To investigate the efficacy of Sanjie Zhentong Capsules combined with cefdinir in the treatment of chronic pelvic inflammatory disease (CPID). Methods Eighty-eight CPID patients admitted to the First Affiliated Hospital of Xinjiang Medical University from January 2022 to November 2024 were enrolled and divided into two groups (via random number table), with 44 cases each. The control group received Cefdinir Capsules (oral, 0.1 g/dose, 3 times daily). Based on this, the treatment group additionally received Sanjie Zhentong Capsules (oral, 4 pills/dose, 3 times daily, 30 min after meals). Both groups were treated for 14 days. Clinical efficacy was evaluated, and pre-treatment and post-treatment scores were compared, including the Depression-Anxiety-Stress Scale-21 (DASS-21), Chronic Pelvic Inflammatory Disease Function Scale (FS-CPID), maximum diameter of pelvic masses, hemorheological indices (plasma viscosity, PV; erythrocyte aggregation index, EAI), and serum levels of interleukin-1β (IL-1β) and IL-6. Results The total effective rate of treatment group was 95.45%, which was higher than that of control group at 81.82% (P < 0.05). Compared with before treatment, the scores of each item of the disease (main symptoms, secondary symptoms, local pelvic signs, etc.) and the total score of both groups decreased after treatment (P < 0.05), and the DASS-21 score and the maximum diameter of pelvic masses also decreased (P < 0.05). The treatment group was lower than the control group (P < 0.05). Compared with before treatment, the FS-CPID scores of both groups of patients increased after treatment (P < 0.05), and the score of the treatment group was higher than that of the control group (P < 0.05). After treatment, the levels of PV, EAI, and serum IL-1β and IL-6 in both groups were lower than those before treatment within the groups (P < 0.05), and the hemorheological indicators and serum factor levels in the treatment group were significantly lower than those in the control group after treatment (P < 0.05). Conclusion The combination of Sanjie Zhentong Capsules and cefdinir effectively alleviates symptoms/signs, promotes pelvic mass resolution, mitigates pelvic circulation disorders and inflammatory responses, and improves overall disease status, quality of life, and psychological well-being in CPID patients.

R984